52545-13-8

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Pyridinone,4-methoxy-(9CI) is used as a building block for the synthesis of various bioactive molecules and pharmaceutical drugs due to its versatile chemical structure and potential to be modified for specific therapeutic applications.
Used in Antiviral Applications:
2(1H)-Pyridinone,4-methoxy-(9CI) is used as an antiviral agent for its potential to inhibit viral replication and reduce the severity of viral infections, contributing to the development of new antiviral therapies.
Used in Antimicrobial Applications:
2(1H)-Pyridinone,4-methoxy-(9CI) is utilized as an antimicrobial agent, leveraging its ability to combat bacterial infections by disrupting essential cellular processes, thereby supporting the creation of new antimicrobial drugs.
Used in Antifungal Applications:
2(1H)-Pyridinone,4-methoxy-(9CI) is employed as an antifungal agent to treat fungal infections, showcasing its potential to inhibit fungal growth and contribute to the development of antifungal medications.
Used in Antioxidant and Anti-inflammatory Research:
2(1H)-Pyridinone,4-methoxy-(9CI) is studied for its potential as an antioxidant to neutralize harmful free radicals and as an anti-inflammatory agent to reduce inflammation, indicating its possible use in the treatment of various inflammatory and oxidative stress-related conditions.
Overall, 2(1H)-Pyridinone,4-methoxy-(9CI) holds promise in medicinal chemistry and drug discovery, with applications spanning from direct therapeutic uses to its role as a key component in the development of novel pharmaceuticals.

InChI:InChI=1/C6H7NO2/c1-9-5-2-3-7-6(8)4-5/h2-4H,1H3,(H,7,8)

Upstream product

• 18677-43-5 2,4-dimethoxypyridine 
• 75608-94-5 5-methoxy-3-oxo-2-azabicyclo<2.2.0>hex-5-one 
• 1122-96-9 4-methoxypyridine N-oxide 
• 1124-33-0 4-nitraminopyridine N-oxide 
• 870854-86-7 3-Methoxy-3-methyl-2-benzenesulfonylpropenenitrile 
• 870854-88-9 4-methoxy-3-(phenylsulfonyl)pyridin-2(1H)-one 
• 74-88-4 methyl iodide 
• 124049-09-8 2-acetoxy-4-methoxypyridine 
• 620-08-6 4-methoxypyridine 

Downstream Products

• 82493-68-3 (1S,4R)-2-Butyl-2-aza-bicyclo[2.2.0]hex-5-en-3-one 
• 82493-66-1 (1α,2β,5β,6α)-3,7-dibutyl-3,7-diazatricyclo[4.2.2.2^2,5]dodeca-9,11-diene-4,8-dione 
• 82493-66-1 (1α,2α,5α,6α)-3,7-dibutyl-3,7-diazatricyclo[4.2.2.2^2,5]dodeca-9,11-diene-4,8-dione 
• 75608-94-5 5-methoxy-3-oxo-2-azabicyclo<2.2.0>hex-5-one 
• 82493-68-3 2-butyl-2-azabicyclo[2.2.0]hex-5-en-3-one 
• 870854-92-5 1-benzyl-4-methoxypyridin-2(1H)-one 
• 41759-19-7 4-methoxy-1-methyl-2-pyridone 
• 1040112-28-4 3-[4-methoxy-2(1H)-pyridonyl]-N-phenylmaleimide 
• 175965-83-0 2-fluoro-4-methoxypyridine 
• 848360-78-1 2-(dimethylamino)-4-methoxypyridin-5-ylboronic acid 
• 586373-19-5 1-benzyl-4-hydroxypyridin-2(1H)-one 
• 1429318-32-0 C₁₂H₁₁NO₂ 
• 108279-83-0 7-methoxy-5-oxo-1a,2,3,5,7a,7b-hexahydro-1H-cyclobutaindolizine 
• 171228-87-8 (1S,4S)-(-)-2-Hydroxymethyl-5-methoxy-3-oxo-2-azabicyclo<2.2.0>hex-5-ene 

Relevant academic research and scientific papers

Photocycloadditions of 4-Methoxy-2-pyridone to Olefins and Synthesis of 1,2-Dihydrocyclobutapyridin-3(4H)-ones

Irradiation of 4-methoxy-2-pyridone (1) in acetone in the presence of electron-rich alkenes afforded the 3-azabicyclooct-4-en-2-ones (2a-c) as the major products, whereas photolyses in the presence of electron-deficient alkenes led to the 2-azabicyclooct-4-en-3-ones (4a,b) as the major products; base treatment of the former adducts gave rise to the novel 1,2-dihydrocyclobutapyridin-3(4H)-ones (3a-c).

SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

PROBLEM TO BE SOLVED: To provide a novel compound having an integrin α4 inhibiting action. SOLUTION: A sulfonamide derivative or pharmaceutically acceptable salt thereof has a structure represented by a general formula (I) using specific substituents A an

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

COMPOUNDS AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Concise total syntheses of variolin B and deoxyvariolin B

The total synthesis of the marine alkaloid variolin B has been achieved in 8 steps and 17% overall yield, starting from commercially available 4-chloro-2-methylthiopyrimidine. The key reaction involves the tandem deoxygenation and cyclization of a triarylmethanol using a combination of triethylsilane and trifluoroacetic acid. In addition, the deoxygenated analogue was prepared in 6 steps and 23% overall yield, starting from the same starting material.

A practical procedure for the selective N-alkylation of 4-alkoxy-2-pyridones and its use in a sulfone-mediated synthesis of N-methyl-4-methoxy-2-pyridone

It has been found that selective N-alkylation of 4-alkoxy-2-pyridones can be achieved under anhydrous, mild conditions with tetrabutylammonium iodide and potassium tert-butoxide being employed as the catalyst and the base, respectively. The procedure was applied to the preparation of 4-methoxy-1-methyl-2-pyridone, a valuable building block for heterocycle synthesis.

Selective intermolecular photo-[4 + 4]-cycloaddition with 2-pyridone mixtures. 2. Preparation of (1α,2β,5β,6α)-3-butyl-9-methoxy-3,7- diazatricyclo[4.2.2.22,5]dodeca-9,11-diene-4,8-dione

Photochemistry of 2-pyridone mixtures can be selective and thereby lead to useful quantities of [4 + 4] cycloaddition cross products. The selective intermolecular reaction described here employs an excess of 4-methoxy-2- pyridone (6), which does not photodimerize but will undergo [4 + 4] cycloaddition with 2-pyridones without a 4-methoxy group such as N-butyl-2- pyridone 12. Isolated yields of the trans product (1α,2α,5β,6α)-3-butyl- 9-methoxy-3,7-diazatricyclo[4.2.2.22,5]dodeca-9,11-diene-4,8-dione (7) are very sensitive to the ratio of the two starting pyridones, and this product has been isolated in yields of up to 51%. This photoreaction produces, in a single step from simple aromatic precursors, a tricyclic product with four stereogenic centers and four distinct functional groups.

Two new methods for 2,3-pyridyne formation

The compounds 2-chloro-4-methoxypyridine and 4-methoxy-2-trifluoromethylsulfonyloxy-3-trimethylsilylpyridine were shown to be relatively efficient precursors for 4-methoxy-2,3-pyridyne as was evidenced by its trapping with furan, 2-methylfuran and 2-methoxyfuran. These findings constitute the first published report of the use of either directed-deprotonation or fluoride-induced elimination to prepare the reactive 2,3-pyridyne intermediate.

Syntheses and Ring-opening Reactions of 5-Alkoxy- and 5-Acetoxy-3-oxo-2-azabicyclohex-5-enes

The efficient photochemical synthesis of 5-alkoxy- and 5-acetoxy-3-oxo-2-azabicyclohex-5-enes (2a-e and f, g), and a new rearrangement reaction of the former compounds (2a-e) to 6-alkoxy-2-pyridones (3a-e), are reported.